CDK6 is altered in 1.24% of medulloblastoma patients with CDK6 Amplification present in 2.27% of all medulloblastoma patients [4].

CDK6 Amplification is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [5].

CDK6 is altered in 1.01% of malignant solid tumor patients with CDK6 Amplification present in 0.59% of all malignant solid tumor patients [4].

CDK6 Amplification is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 6 are open and 0 are closed. Of the trials that contain CDK6 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open) [5].

CDK6 is altered in 1.49% of malignant glioma patients with CDK6 Amplification present in 1.48% of all malignant glioma patients [4].

CDK6 Amplification is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain CDK6 Amplification and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) and 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

CDK6 is altered in 6.25% of large cell/anaplastic medulloblastoma patients with CDK6 Amplification present in 25.0% of all large cell/anaplastic medulloblastoma patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 1.3% of central nervous system embryonal neoplasm patients with CDK6 Amplification present in 1.57% of all central nervous system embryonal neoplasm patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 1.62% of glioblastoma patients with CDK6 Amplification present in 1.56% of all glioblastoma patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [5].

CDK6 is altered in 0.81% of breast carcinoma patients with CDK6 Amplification present in 0.41% of all breast carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK6 Amplification and breast carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

CDK6 is altered in 0.51% of soft tissue sarcoma patients with CDK6 Amplification present in 0.22% of all soft tissue sarcoma patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK6 is altered in 0.49% of ovarian carcinoma patients with CDK6 Amplification present in 0.1% of all ovarian carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Amplification and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 6.13% of adenocarcinoma of the gastroesophageal junction patients with CDK6 Amplification present in 6.35% of all adenocarcinoma of the gastroesophageal junction patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 3.7% of gallbladder carcinoma patients with CDK6 Amplification present in 3.86% of all gallbladder carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.75% of anaplastic ependymoma patients with CDK6 Amplification present in 3.45% of all anaplastic ependymoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 2.19% of gastric adenocarcinoma patients with CDK6 Amplification present in 1.88% of all gastric adenocarcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.43% of anaplastic astrocytoma patients with CDK6 Amplification present in 1.45% of all anaplastic astrocytoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.36% of bile duct carcinoma patients with CDK6 Amplification present in 1.45% of all bile duct carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.34% of pancreatic carcinoma patients with CDK6 Amplification present in 1.41% of all pancreatic carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.09% of high-grade glioma, NOS patients with CDK6 Amplification present in 1.28% of all high-grade glioma, NOS patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.38% of diffuse glioma patients with CDK6 Amplification present in 1.27% of all diffuse glioma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.83% of head and neck squamous cell carcinoma patients with CDK6 Amplification present in 1.24% of all head and neck squamous cell carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.87% of esophageal squamous cell carcinoma patients with CDK6 Amplification present in 0.92% of all esophageal squamous cell carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.2% of osteosarcoma patients with CDK6 Amplification present in 0.87% of all osteosarcoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.42% of head and neck carcinoma patients with CDK6 Amplification present in 0.83% of all head and neck carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.52% of melanoma patients with CDK6 Amplification present in 0.74% of all melanoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.95% of cancer patients with CDK6 Amplification present in 0.57% of all cancer patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Amplification and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 is altered in 1.03% of non-small cell lung carcinoma patients with CDK6 Amplification present in 0.43% of all non-small cell lung carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.05% of lung carcinoma patients with CDK6 Amplification present in 0.42% of all lung carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.77% of cervical carcinoma patients with CDK6 Amplification present in 0.3% of all cervical carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.78% of colorectal carcinoma patients with CDK6 Amplification present in 0.26% of all colorectal carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.09% of squamous cell lung carcinoma patients with CDK6 Amplification present in 0.22% of all squamous cell lung carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CDK6 is altered in 0.83% of bladder carcinoma patients with CDK6 Amplification present in 0.2% of all bladder carcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.88% of malignant uterine neoplasm patients with CDK6 Amplification present in 0.13% of all malignant uterine neoplasm patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.45% of ovarian epithelial tumor patients with CDK6 Amplification present in 0.09% of all ovarian epithelial tumor patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 0.62% of anaplastic oligodendroglioma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.88% of chondrosarcoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.11% of endometrial endometrioid adenocarcinoma patients [4].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

CDK6 Amplification is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Amplification and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].